Innohep (Tinzaparin Sodium)

Innohep (tinzaparin sodium) is used in the management of venous thromboembolism and related cardiovascular conditions.

• Deep vein thrombosis (post‑operative): prevents clot formation and extension in patients after major surgery.
• Acute deep vein thrombosis: treats existing clots by enhancing natural anticoagulation.
• Pulmonary embolism: both prevents new emboli and aids in the treatment of established emboli.
• Acute coronary syndrome: reduces the risk of thrombotic complications during and after the event.

• Tinzaparin sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). By selectively blocking factor Xa, the drug reduces thrombin generation, thereby limiting fibrin clot formation while preserving a degree of normal hemostasis. The enhanced antithrombin affinity also results in more predictable pharmacokinetics and dosing.

Tinzaparin sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the subcutaneous injection site.
• Bruising or hematoma: localized bleeding under the skin.
• Minor bleeding: such as epistaxis or gum bleeding.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening bleeding in internal organs or the central nervous system.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline that can paradoxically cause clotting.
• Spinal or epidural hematoma: bleeding in the spinal canal, especially after neuraxial anesthesia.
• Severe allergic reaction: anaphylaxis or serum sickness‑like symptoms.

When using Innohep, several safety considerations should be observed to minimize risks.

• Renal impairment: assess kidney function and adjust dose or monitor anti‑Xa levels.
• History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence.
• Concurrent anticoagulants: increased bleeding risk when combined with warfarin, direct oral anticoagulants, or thrombolytics.
• Invasive procedures: discontinue before surgery or epidural catheter placement to reduce bleeding complications.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Tinzaparin sodium can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulation may cause severe bleeding.
• Thrombolytic agents (e.g., alteplase): combined use markedly raises hemorrhage risk.
• Neuraxial anesthesia or spinal puncture: concurrent use can precipitate spinal hematoma.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance mucosal bleeding.
• Antiplatelet agents (e.g., clopidogrel, aspirin): increase overall bleeding tendency.